{"entity":{"id":"expres2ion-biotechnologies","kind":"company","name":"ExpreS2ion Biotechnologies","aka":["ExpreS2ion"],"tldr":"ExpreS2ion Biotechnologies makes ES2B-C001, a vaccine that trains the immune system to recognise HER2, a protein found on some breast and other cancers. It is in a first trial in people with HER2-expressing breast cancer that has spread.","summary":"ExpreS2ion Biotechnologies is a clinical-stage company listed on the Nasdaq First North Growth Market in Sweden, with research and development in Hørsholm, Denmark, and a holding company address in Helsingborg, Sweden. It develops immunotherapies using its proprietary ExpreS2 protein expression system. Its lead programme ES2B-C001 is an active immunotherapy for HER2-expressing cancers that combines HER2 antigens with a virus-like particle delivery system and is designed to target all four extracellular domains of the HER2 receptor; a first-in-human phase 1 trial assesses safety with or without an adjuvant in patients with HER2-expressing metastatic breast cancer. Its first registered cancer trial, NCT06746688, was posted on ClinicalTrials.gov in December 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://expres2ionbio.com/"},{"label":"ClinicalTrials.gov: first-in-human trial of ES2B-C001 in HER2-expressing metastatic breast cancer (NCT06746688)","url":"https://clinicaltrials.gov/study/NCT06746688"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine"],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website.","The company website blocked automated requests; its content was read through a fetch tool that summarises pages, so wording was checked only against that summary and the registry record.","The ticker symbol was not shown on the page read and is not recorded.","No financing rounds were read; none are recorded.","Read on 29 October 2026."],"hq":"Hørsholm","country":"DK","companyType":"biotech","website":"https://expres2ionbio.com/","stage":"public","investors":[],"funding":[]},"route":"/companies/expres2ion-biotechnologies/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}]}}